Takaisin

Efficacy of low-level laser therapy (LLLT) in the prevention and treatment of radiation-induced oral mucositis

Näytönastekatsaukset
Venla Loimu
26.5.2026

Näytön aste: B

Low-level laser therapy probably reduces incidence and severity of radiation induced mucositis. It may also alleviate mucositis related pain.

A meta-analysis of 14 randomized trials (869 patients) found that low-level laser therapy (LLLT) given during head and neck (chemo)radiotherapy significantly reduced the incidence, severity, and pain of oral mucositis, although standardized protocols are still needed «Shen B, Zhou Y, Wu D, ym. Efficacy of photobiomodu...»1.

Evidence from Western countries is limited. A small double-blind RCT from Spain showed significantly less mucositis with LLLT compared with controls, without increased side effects «Marín-Conde F, Castellanos-Cosano L, Pachón-Ibañez...»2. In contrast, the UK-based Phase III LiTEFORM trial did not demonstrate clear benefit, largely due to under-recruitment and limited statistical power «Nugent M, Bryant V, Butcher C, ym. Photobiomodulat...»3.

MASCC/ISOO guidelines (2020) recommend LLLT for preventing oral mucositis in head and neck patients receiving radiotherapy or chemoradiotherapy «Elad S, Cheng KKF, Lalla RV, ym. MASCC/ISOO clinic...»4. Benefits have also been observed in patients receiving other antineoplastic treatments «Cruz AR, Minicucci EM, Betini M, ym. Efficacy of p...»5.

The evidence comes from systematic reviews and meta-analysis of RCT studies and single RCT studies, the level of evidence is downgraded one level due to study limitations (small studies and varying treatment protocols) and imprecision.

Taulukko 1. Description of the included studies
Reference Study type Population Intervention and comparison Outcomes Risk of bias «Additional comments for included studies...»2
«Shen B, Zhou Y, Wu D, ym. Efficacy of photobiomodu...»1 SR/MA Patients with head and neck cancer, aged ≥18yrs, scheduled for (chemo)radiotherapy Low level laser therapy (Wavelength range 632.8-940 nm, power range 10-100 mW) 3-5 sessions/week (3/week, 2 studies; 5/week, 11 studies; NS/1 study) for 2-10 weeks (2 weeks, 1 study; 5 weeks, 1 study; 6 weeks, 4 studies; 6.5 weeks; 2 studies; 7 weeks, 1 study; 45 days, 1 study; mean 45.7 days, 1 study; 10 weeks, 1 study; NS, 2 studies)vs. standard oral care, including mouthwash, analgesics +/- sham 1.Incidence of OM (according to RTOG, CTCAE, WHO)
2. Incidence of severe (Grade ≥3) OM
3. OM-related pain (VAS)
Low
«Marín-Conde F, Castellanos-Cosano L, Pachón-Ibañez...»2 RCT Patients with oral/oropharyngeal SCC scheduled for chemoradiotherapy Low level laser therapy (940 nm, 500 mW) vs. sham Grade, appearance, and remission of mucositis High
«Nugent M, Bryant V, Butcher C, ym. Photobiomodulat...»3 RCT Patients aged ≥18yrs scheduled for H&N radiotherapy with ≥60Gy Low level laser therapy (660 nm, 50mW) vs. sham The mean Oral Mucositis Weekly Questionnaire-Head and Neck Cancer score at 6 weeks. High

RCT=randomized controlled trial; SR=systematic review; MA=meta-analysis, OM=oral mucositis

Taulukko 2. Additional comments for included studies
Reference Comments
«Shen B, Zhou Y, Wu D, ym. Efficacy of photobiomodu...»1 Seven randomized controlled trials from Brazil, four from India, one each from UK, Spain, and Egypt. Seven double-blind trials, one triple-blind trial, two phase III trials.
High heterogeneity in mucositis incidence, high variation of PBMT parameters among studies, inconsistency in outcome measures used across studies.
«Marín-Conde F, Castellanos-Cosano L, Pachón-Ibañez...»2 Small sample size. Data analyzed only for 26 of the initially recruited 36 patients due to discontinuation of the follow-up. Unbalanced patient characteristics across the treatment arms.
«Nugent M, Bryant V, Butcher C, ym. Photobiomodulat...»3 Recruitment target not met: Lack of statistical power

Results

Taulukko 3. Efficacy of LLLT/PBM in the prevention and treatment of OM
Reference Number of studies and number of patients (I/C) Follow-up time Absolute number of events (%) I Absolute number of events (%) C Relative effect (95% CI)
Level of evidence: moderate
The quality of evidence is downgraded due to study limitations, imprecision.
«Shen B, Zhou Y, Wu D, ym. Efficacy of photobiomodu...»1 11 studies
778 pts (392 /386)
7 weeks N/A N/A -Incidence of mucositis during (chemo)radiotherapy RR=0.49(0.25-0.97)
-Occurrence of severe mucositis until the completion of the treatment RR=0.45(0.24-0.85)
«Marín-Conde F, Castellanos-Cosano L, Pachón-Ibañez...»2 26 pts (11/15) 5 weeks No mucositis in 72.7% vs. 20%; 40% of controls had mucositis grade 2 (p<0.01)
-No differences in medication use or side effects (p>0.05)
«Nugent M, Bryant V, Butcher C, ym. Photobiomodulat...»3 87 pts (44/43) 6 weeks Mean mucositis scores 33.2 (SD 10) in the LLLT group vs. 27.4 (SD 13.8) in the sham group

I=intervention; C=comparison; CI=confidence interval

Taulukko 4. Oral mucositis related pain (VAS) Symptoms and QoL
Reference Number of studies and number of patients (I/C) Follow-up time Absolute number of events (%) I Absolute number of events (%) C Relative effect (95% CI)
Level of evidence: high
The quality of evidence is downgraded due to study limitations.
«Cruz AR, Minicucci EM, Betini M, ym. Efficacy of p...»5 5 studies
117/118 pts
Control=sham+oral care (105 pts), oral care (13 pts)
N/A N/A -Alleviation of OM-related pain
WMD –1,09 [-1.38- -0.880], p<0.00001

I=intervention; C=comparison; CI=confidence interval, WMD=weighted mean difference

Kirjallisuutta

  1. Shen B, Zhou Y, Wu D, ym. Efficacy of photobiomodulation therapy in the management of oral mucositis in patients with head and neck cancer: A systematic review and meta-analysis of randomized controlled trials. Head Neck 2024;46(4):936-950 «PMID: 38265122»PubMed
  2. Marín-Conde F, Castellanos-Cosano L, Pachón-Ibañez J, ym. Photobiomodulation with low-level laser therapy reduces oral mucositis caused by head and neck radio-chemotherapy: prospective randomized controlled trial. Int J Oral Maxillofac Surg 2019;48(7):917-923 «PMID: 30591391»PubMed
  3. Nugent M, Bryant V, Butcher C, ym. Photobiomodulation in the management of oral mucositis for adult head and neck cancer patients receiving irradiation: the LiTEFORM RCT. Health Technol Assess 2022;26(46):1-172 «PMID: 36484364»PubMed
  4. Elad S, Cheng KKF, Lalla RV, ym. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2020;126(19):4423-4431 «PMID: 32786044»PubMed
  5. Cruz AR, Minicucci EM, Betini M, ym. Efficacy of photobiomodulation in the treatment of oral mucositis in patients undergoing antineoplastic therapy: systematic review and meta-analysis. Support Care Cancer 2023;31(12):645 «PMID: 37853254»PubMed